J.Safra Asset Management Corp Boosts Stock Position in argenx SE (NASDAQ:ARGX)

J.Safra Asset Management Corp boosted its holdings in shares of argenx SE (NASDAQ:ARGX) by 123.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 273 shares of the company’s stock after acquiring an additional 151 shares during the quarter. J.Safra Asset Management Corp’s holdings in argenx were worth $169,000 as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. Whipplewood Advisors LLC purchased a new position in argenx during the 4th quarter valued at $37,000. Global Retirement Partners LLC boosted its holdings in argenx by 369.2% during the 4th quarter. Global Retirement Partners LLC now owns 61 shares of the company’s stock valued at $38,000 after acquiring an additional 48 shares during the period. Jones Financial Companies Lllp boosted its holdings in argenx by 1,016.7% during the 4th quarter. Jones Financial Companies Lllp now owns 67 shares of the company’s stock valued at $41,000 after acquiring an additional 61 shares during the period. Venturi Wealth Management LLC purchased a new position in argenx during the 4th quarter valued at $66,000. Finally, Nkcfo LLC purchased a new stake in shares of argenx in the 4th quarter worth $68,000. Hedge funds and other institutional investors own 60.32% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on ARGX. HC Wainwright upped their target price on argenx from $717.00 to $720.00 and gave the stock a “buy” rating in a report on Friday, February 28th. Robert W. Baird upped their target price on argenx from $650.00 to $680.00 and gave the stock a “neutral” rating in a report on Tuesday. Wolfe Research upgraded argenx from a “peer perform” rating to an “outperform” rating and set a $697.00 target price for the company in a report on Tuesday, November 12th. Truist Financial reiterated a “buy” rating and issued a $700.00 target price (up from $660.00) on shares of argenx in a report on Tuesday, January 14th. Finally, Piper Sandler upped their target price on argenx from $620.00 to $725.00 and gave the stock an “overweight” rating in a report on Tuesday, January 7th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $662.83.

argenx Price Performance

Shares of NASDAQ:ARGX opened at $636.49 on Thursday. The business’s 50-day moving average is $642.34 and its 200 day moving average is $592.58. argenx SE has a 1 year low of $349.86 and a 1 year high of $678.21. The firm has a market capitalization of $38.67 billion, a P/E ratio of -723.28 and a beta of 0.58.

argenx (NASDAQ:ARGX) last announced its earnings results on Thursday, February 27th. The company reported $1.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.98 by $0.60. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. The company had revenue of $761.22 million for the quarter, compared to analyst estimates of $678.52 million. On average, analysts expect that argenx SE will post 3.13 EPS for the current year.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.